SKCC's Drs. Marlana Orloff, Rino Seedor, & Takami Sato summarize the experience with tebentafusp, a first in class bi-specific T cell engager, as well as highlight bi-specifics as a novel treatment strategy in #UvealMelanoma: ow.ly/RE0y50JKFz9 @cgtnature #ResearchWednesday

Our paper was finally published on the first day of the new year! The team at Jefferson has done incredible work to improve the survival of MUM patients #uvealmelanoma #joiningtheteamsoon… instagram.com/p/B69eeN_FGcQH…